Tiagabine

DEA Class;  Rx

Common Brand Names; Gabitril

Hypersensitivity

Dizziness (26-30%)

Asthenia (16-20%)

Somnolence (16-20%)

Nausea (11-15%)

Abdominal pain (6-10%)

Diarrhea (6-10%)

Vomiting (6-10%)

Nervousness (6-10%)

Pharyngitis (6-10%)

Tremor (6-10%)

Insomnia (6-10%)

Rash (1-5%)

Pruritis (1-5%)

Ataxia (1-5%)

Confusion (1-5%)

Speech d/o (1-5%)

Paresthesia (1-5%)

Depr’n (1-5%)

Pain (1-5%)

Increased appetite (1-5%)

Hostility (1-5%)

Nystagmus (1-5%)

Bullous dermatitis

Vision blurred

Antiepileptic drugs (AED) increase risk of suicidal thoughts or behavior in patients taking them for any indication; patients treated with any AED for any indication should be monitored for emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior

Risk of seizures if used in patients without epilepsy (when used off-label in psychiatric disorder); in nonepileptic patients who develop seizures while on therapy, discontinue therapy and evaluate patients for underlying seizure disorder

Should not be abruptly discontinued because of possibility of increasing seizure frequency

Use without enzyme-inducing antiepileptic drugs results in about twice the blood levels than what dosage recommendations are based on

Because clearance of tiagabine is reduced in patients with liver disease, dosage reduction may be necessary in these patients

Adverse events most often associated with therapy were related to central nervous system; the most significant of these can be classified into 2 general categories: 1) impaired concentration, speech or language problems, and confusion (effects on thought processes); and 2) somnolence and fatigue (effects on level of consciousness)

Moderately severe to incapacitating generalized weakness reported; resolves after reduction in dose or discontinuation of thearpy

Pregnancy Category: C

Lactation: Unknown; use caution